Literature DB >> 27316344

A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.

Kenneth Grasing1.   

Abstract

The cholinergic system plays important roles in both learning and addiction. Medications that modify cholinergic tone can have pronounced effects on behaviors reinforced by natural and drug reinforcers. Importantly, enhancing the action of acetylcholine (ACh) in the nucleus accumbens and ventral tegmental area (VTA) dopamine system can either augment or diminish these behaviors. A threshold model is presented that can explain these seemingly contradictory results. Relatively low levels of ACh rise above a lower threshold, facilitating behaviors supported by drugs or natural reinforcers. Further increases in cholinergic tone that rise above a second upper threshold oppose the same behaviors. Accordingly, cholinesterase inhibitors, or agonists for nicotinic or muscarinic receptors, each have the potential to produce biphasic effects on reward behaviors. Pretreatment with either nicotinic or muscarinic antagonists can block drug- or food- reinforced behavior by maintaining cholinergic tone below its lower threshold. Potential threshold mediators include desensitization of nicotinic receptors and biphasic effects of ACh on the firing of medium spiny neurons. Nicotinic receptors with high- and low- affinity appear to play greater roles in reward enhancement and inhibition, respectively. Cholinergic inhibition of natural and drug rewards may serve as mediators of previously described opponent processes. Future studies should evaluate cholinergic agents across a broader range of doses, and include a variety of reinforced behaviors. Published by Elsevier B.V.

Entities:  

Keywords:  Acetylcholine; Acetylcholinesterase inhibitors; Cocaine; Donepezil; Galantamine; Muscarinic receptor; Nicotinic receptor; Reinforcement (psychology); Rivastigmine; Self-administration

Mesh:

Substances:

Year:  2016        PMID: 27316344      PMCID: PMC4970908          DOI: 10.1016/j.bbr.2016.06.022

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  210 in total

1.  Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice.

Authors:  Weilie Zhang; Masahisa Yamada; Jesus Gomeza; Anthony S Basile; Jürgen Wess
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

2.  Long-term effects of chronic nicotine exposure on brain nicotinic receptors.

Authors:  Morgane Besson; Sylvie Granon; Monica Mameli-Engvall; Isabelle Cloëz-Tayarani; Nicolas Maubourguet; Anne Cormier; Pierre Cazala; Vincent David; Jean-Pierre Changeux; Philippe Faure
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 3.  The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies.

Authors:  Inge Klinkenberg; Arjan Blokland
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

4.  Neurocognitive deficits in cocaine users: a quantitative review of the evidence.

Authors:  Diana Jovanovski; Suzanne Erb; Konstantine K Zakzanis
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

5.  Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing α4 and α6 subunits.

Authors:  Liwang Liu; Rubing Zhao-Shea; J Michael McIntosh; Paul D Gardner; Andrew R Tapper
Journal:  Mol Pharmacol       Date:  2012-01-05       Impact factor: 4.436

6.  The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study.

Authors:  James Poling; Bruce Rounsaville; Kishorchandra Gonsai; Kevin Severino; Mehmet Sofuoglu
Journal:  Am J Addict       Date:  2010 Sep-Oct

7.  Homomeric and native alpha 7 acetylcholine receptors exhibit remarkably similar but non-identical pharmacological properties, suggesting that the native receptor is a heteromeric protein complex.

Authors:  R Anand; X Peng; J Lindstrom
Journal:  FEBS Lett       Date:  1993-07-26       Impact factor: 4.124

8.  Dose-related effects of the acetylcholinesterase inhibitor tacrine on cocaine and food self-administration in rats.

Authors:  Kenneth Grasing; Shuangteng He; Yungao Yang
Journal:  Psychopharmacology (Berl)       Date:  2007-10-05       Impact factor: 4.530

9.  Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.

Authors:  Joshua H Balsters; Redmond G O'Connell; Mary P Martin; Alessandra Galli; Sarah M Cassidy; Sophia M Kilcullen; Sonja Delmonte; Sabina Brennan; Jim F Meaney; Andrew J Fagan; Arun L W Bokde; Neil Upton; Robert Lai; Marc Laruelle; Brian Lawlor; Ian H Robertson
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Acetylcholine, drug reward and substance use disorder treatment: intra- and interindividual striatal and accumbal neuron ensemble heterogeneity may explain apparent discrepant findings.

Authors:  Janine M Prast; Kai K Kummer; Constanze M Barwitz; Christian Humpel; Georg Dechant; Gerald Zernig
Journal:  Pharmacology       Date:  2012-09-25       Impact factor: 2.547

View more
  13 in total

1.  Letter to the Editor: A Novel Therapeutic for Opioid Use Disorder Targeting the Cholinergic System.

Authors:  Scott J Moeller; Anissa Abi-Dargham
Journal:  Am J Addict       Date:  2019-06-04

2.  Striatal Cholinergic Interneurons Are a Novel Target of Corticotropin Releasing Factor.

Authors:  Julia C Lemos; Jung Hoon Shin; Veronica A Alvarez
Journal:  J Neurosci       Date:  2019-05-20       Impact factor: 6.167

3.  Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.

Authors:  Kathleen M Carroll; Charla Nich; Elise E DeVito; Julia M Shi; Mehmet Sofuoglu
Journal:  J Clin Psychiatry       Date:  2018 Jan/Feb       Impact factor: 4.384

4.  Profound alteration in reward processing due to a human polymorphism in CHRNA5: a role in alcohol dependence and feeding behavior.

Authors:  Morgane Besson; Benoît Forget; Caroline Correia; Rodolphe Blanco; Uwe Maskos
Journal:  Neuropsychopharmacology       Date:  2019-07-09       Impact factor: 7.853

5.  Extracellular dopamine, acetylcholine, and activation of dopamine D1 and D2 receptors after selective breeding for cocaine self-administration in rats.

Authors:  Haiyang Xu; Sasmita Das; Marc Sturgill; Colin Hodgkinson; Qiaoping Yuan; David Goldman; Kenneth Grasing
Journal:  Psychopharmacology (Berl)       Date:  2017-05-26       Impact factor: 4.530

6.  The muscarinic agonist pilocarpine modifies cocaine-reinforced and food-reinforced responding in rats: comparison with the cholinesterase inhibitor tacrine.

Authors:  Kenneth W Grasing; Haiyang Xu; Jessica Y Idowu
Journal:  Behav Pharmacol       Date:  2019-09       Impact factor: 2.293

7.  Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder.

Authors:  Elise E DeVito; Kathleen M Carroll; Theresa Babuscio; Charla Nich; Mehmet Sofuoglu
Journal:  J Subst Abuse Treat       Date:  2019-08-16

8.  Multiple cholinesterase inhibitors have antidepressant-like properties in the mouse forced swim test.

Authors:  Paul J Fitzgerald; Pho J Hale; Anjesh Ghimire; Brendon O Watson
Journal:  Behav Brain Res       Date:  2021-04-25       Impact factor: 3.332

9.  Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.

Authors:  Kathleen M Carroll; Elise E DeVito; Sarah W Yip; Charla Nich; Mehmet Sofuoglu
Journal:  Am J Addict       Date:  2019-06-04

Review 10.  Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders.

Authors:  Ken W Grasing; Kim Burnell; Alok De
Journal:  Behav Pharmacol       Date:  2022-03-23       Impact factor: 2.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.